Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorFerrer-Cardona, M. (Marta)-
dc.creatorGimenez-Arnau, A. (Ana)-
dc.creatorSaldana, D. (Diego)-
dc.creatorJanssens, N. (Nico)-
dc.creatorBalp, M.M. (Maria Magdalena)-
dc.creatorKhalil, S. (Sam)-
dc.creatorRisson, V. (Valéry)-
dc.date.accessioned2023-03-30T09:42:40Z-
dc.date.available2023-03-30T09:42:40Z-
dc.date.issued2018-
dc.identifier.citationFerrer, M. (Marta); Gimenez-Arnau, A. (Ana); Saldana, D. (Diego); et al. "Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis". Journal of allergy and clinical immunology. In practice. 6 (4), 2018, 1191 - 1197.e5es
dc.identifier.issn2213-2198-
dc.identifier.urihttps://hdl.handle.net/10171/65812-
dc.description.abstractBACKGROUND: Omalizumab is highly effective in controlling chronic spontaneous urticaria (CSU) symptoms; however, patients can experience symptom return on treatment discontinuation. Pivotal clinical trials have identified 2 categories of patients who experience symptom return: rapid and slow. OBJECTIVE: The objective of this study was to identify potential predictors of the speed of symptom return after stopping omalizumab treatment. METHODS: Phase III randomized controlled trial (RCT) data from ASTERIA I (n [ 319; 6 3 4 weekly injections of omalizumab 75, 150, 300 mg or placebo; NCT01287117) and ASTERIA II (n [ 323; 3 3 4 weekly injections of omalizumab 75, 150, 300 mg, or placebo; NCT01292473) were pooled to identify predictors of symptom return after stopping omalizumab treatment (16-week follow-up). The least absolute shrinkage and selection operator regularization regression model was used to select predictive variables, and relapse probability was represented using heatmap visualizations. Model accuracy was tested using data from the GLACIAL phase III RCT (n [ 336; 6 3 4 weekly injections of omalizumab 300 mg or placebo; NCT0126493). RESULTS: Of 746 variables assessed, 2 were selected by the model as predictors of symptom return: baseline urticaria activity score over 7 days (UAS7) and early area above the curve (AAC; determined by plotting the UAS7 scores across time points). Results suggest that high baseline UAS7 and low UAS7 AAC (slow decrease of symptoms) indicate a higher probability of rapid symptom return than low baseline UAS7 and high UAS7 AAC. CONCLUSIONS: These results suggest that the probability of rapid symptom return in patients with CSU who discontinue treatment with omalizumab can be estimated based on baseline UAS7 and early treatment response.es_ES
dc.language.isoenges_ES
dc.publisherElsevier BVes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectChronic spontaneous urticariaes_ES
dc.subjectLASSO modeles_ES
dc.subjectUrticaria activity scorees_ES
dc.subjectChronic urticariaes_ES
dc.subjectSymptom returnes_ES
dc.subjectOmalizumabes_ES
dc.subjectTreatment discontinuationes_ES
dc.titlePredicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/)es_ES
dc.identifier.doi10.1016/j.jaip.2018.04.003-
dadun.citation.endingPage1197.e5es_ES
dadun.citation.number4es_ES
dadun.citation.publicationNameJournal of allergy and clinical immunology. In practicees_ES
dadun.citation.startingPage1191es_ES
dadun.citation.volume6es_ES
dc.identifier.pmid29655772-

Ficheros en este ítem:
Vista previa
Fichero
1-s2.0-S2213219818302733-main.pdf
Descripción
Tamaño
2.11 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.